Peptide Interaction Checker
Select 2–5 items to compare sourced notes and evidence gaps. Results distinguish studied treatment settings, product-label warnings and unassessed combinations. They are not a complete medication review, validated severity scores or a recommendation to combine treatments.
Peptide Interaction Checker
Select 2–5 items to compare evidence notes. This is a limited educational reference, not a complete interaction screen or permission to combine medicines. Categories describe the note, not a validated severity score.
Start typing to search and select items
Medical Disclaimer: This tool is for educational purposes only and does not constitute medical advice. Notes distinguish product labeling, human studies, preclinical findings and unassessed combinations. The tool is incomplete and does not assess doses, routes, timing, all medicines or medical conditions.
Always consult with a qualified healthcare provider before starting or combining any peptides, supplements, or medications. Individual responses vary based on health status, genetics, dosing, and other factors.
Bring the exact product names, formulations, doses and all medicines or supplements to a pharmacist or prescriber. Do not start, stop, combine or adjust treatment based on a result here.
Understanding Peptide Interactions
Peptide interactions occur when two or more substances affect how each other is absorbed, metabolized, or processed in the body. Just like traditional pharmaceuticals, peptides can interact with medications, supplements, and other peptides in ways that may enhance, reduce, or alter their effects.
An interaction can alter benefits or adverse effects, but a shared pathway alone does not establish its clinical importance. A combination studied in one population is not automatically suitable for another. Here, limited or unassessed means this tool has not established a pair assessment—not that no interaction exists.
Key factors affecting interactions include:
- How substances are metabolized (liver, kidneys, GI tract)
- Receptor overlap and mechanism of action
- Changes to absorption and gastric emptying
- Effects on blood coagulation and cardiovascular function
- Hormonal and metabolic pathway interactions
- Individual health status, genetics, and comorbidities
Common Peptide Stacks and Their Safety
A "stack" means using multiple substances together, often with a proposed complementary benefit. We retain discussion of emerging practice, but distinguish those proposals from human combination evidence. Monitoring one biomarker cannot establish the safety of an entire stack.
The Wolverine Stack (BPC-157 + TB-500)
The BPC-157/TB-500 pairing, sometimes discussed alongside GHK-Cu as a "recovery trinity," is an emerging-practice topic. Proposed repair mechanisms do not establish superior human recovery or combined safety. For example, original BPC-157 research on NSAID-related gastrointestinal injury was conducted in rats; it does not show that adding BPC-157 protects people taking NSAIDs. TB-500 products also should not be assumed identical to full-length thymosin beta-4 studied elsewhere.
Growth Hormone Secretagogue Stacks
CJC-1295, ipamorelin, sermorelin, GHRP-2, GHRP-6 and MK-677 are not interchangeable names. The selector includes a CJC-1295/ipamorelin combination, and different CJC formulations complicate interpretation. Combining GH-related agents is discussed in emerging practice, but this tool has not established the specific combined regimens. Neither receptor overlap nor a monitored IGF-1 value establishes compatibility.
GLP-1 Agonists: The Critical Rule
Do not use this tool to combine GLP-1-based treatments. The Wegovy, Zepbound and Saxenda labels do not recommend these combinations. This is not evidence for a quantified hypoglycemia risk from every pair. Retatrutide trial results do not establish a stacking protocol, and switching requires specific prescriber instructions rather than a universal washout interval.
Visit our guide on peptide stacks for discussion of reported combinations and their evidence limitations.
Peptides and Prescription Medications
Combining peptides with existing medications is common but requires careful consideration. The most important interactions to understand are:
GLP-1 Agonists and Insulin
The Ozempic, Zepbound and Victoza labels identify hypoglycemia considerations with insulin. A prescriber may reduce insulin or change monitoring, but there is no universal percentage selected by this tool. These medicines do not replace required insulin, and a type 2 diabetes study is not a type 1 diabetes treatment instruction.
Growth Hormone Secretagogues and Insulin
An original randomized MK-677 trial in healthy older adults found increased fasting glucose and reduced insulin sensitivity. It was not an insulin-combination trial and does not establish the effect of every GH-related peptide or the direction of a personal insulin adjustment.
Blood Thinners and NSAIDs with Peptides
Warfarin labeling identifies increased bleeding risk with NSAIDs, including ibuprofen and naproxen. That is a drug-specific documented warning. Warfarin and heparin are not interchangeable; proposed mechanisms for research peptides do not establish a human anticoagulant interaction. Bring the exact medicines and peptide products to the pharmacist or prescriber.
Thyroid Medication and GLP-1s
Formulation matters. An oral-semaglutide study in healthy subjects found increased thyroxine exposure with coadministered levothyroxine. That does not establish a universal interaction magnitude for injected products or every thyroid medicine. Labels discuss gastric emptying and oral medication considerations; this tool does not prescribe four-hour separation. Confirm the exact products, administration instructions and monitoring plan with the pharmacist.
Antidepressants (SSRIs) and Neuromodulating Peptides
Selank and Semax are discussed in emerging neuropharmacology and anecdotal practice. Mechanistic claims do not establish a clinical SSRI interaction, improved effects or a serotonin-syndrome risk estimate. This tool has not established those human combination assessments; it should not be used to alter psychiatric treatment.
For more details on specific medication interactions, see our GLP-1 side effects guide.
When to Consult a Healthcare Provider
Before starting or combining peptides with medications, you should consult a healthcare provider if any of the following apply:
- You have type 1 or type 2 diabetes or take blood sugar medication
- You take blood thinners or have a bleeding disorder
- You have cardiovascular disease or take blood pressure medications
- You take psychiatric medications (SSRIs, antipsychotics, mood stabilizers)
- You have thyroid disease and take thyroid replacement
- You are pregnant, breastfeeding, or planning pregnancy
- You have kidney or liver disease
- You are over 65 or have multiple comorbidities
- You experience side effects or adverse reactions
- You are unsure about interaction severity or dosing
A pharmacist or prescribing clinician can review the full medication list, exact formulations and relevant conditions. The tool considers pairs only; it does not evaluate all multi-drug effects, pregnancy, diagnoses or whether a treatment is appropriate. Review is not limited to people taking three or more substances.
For general peptide safety information, read our comprehensive peptide safety guide.
Related Safety Guides
Explore our comprehensive library of peptide safety, efficacy, and protocol guides:
- Are Peptides Safe? — Overview of peptide safety profiles and regulatory status
- Peptide Stacks & Protocols — Reported combinations and evidence considerations
- Peptide Side Effects — Common adverse reactions and how to manage them
- BPC-157 & TB-500 Blend Guide — Deep dive into the "Wolverine Stack"
- GLP-1 Side Effects & Safety — Semaglutide, tirzepatide, liraglutide safety and interactions
- Peptide Knowledge Quiz — Test your understanding of peptides and safety
Frequently Asked Questions
Weight-management product labels do not recommend combining GLP-1-based medicines. Retatrutide trial results do not establish a stacking protocol. This tool does not quantify the risk of a particular combination or choose a switching or washout schedule; obtain product-specific instructions from the prescriber.
The pairing is discussed as the Wolverine Stack in emerging recovery practice. This tool has not established a human combination assessment showing improved recovery or safety. A complementary mechanism or lack of reports here is not a compatibility clearance.
Provide the exact peptide or medicine, formulation, insulin regimen, glucose records and other treatments. Product labels identify increased hypoglycemia risk when certain GLP-1 medicines are combined with insulin, and the prescriber may adjust treatment. This tool does not select a percentage reduction. Findings from one GH-secretagogue study cannot determine every peptide's effect.
The answer depends on the exact drug and peptide. Warfarin labeling identifies increased bleeding risk with NSAIDs; this is an established medication issue, not proof that BPC-157, TB-500 or GHK-Cu has a particular anticoagulant effect in people. Unassessed pairings in this tool need a complete medication review, not an assumption of no interaction.
Ask a pharmacist or prescriber before making a combination or treatment change. Review is especially important with insulin or other glucose-lowering medicines, anticoagulants, cardiovascular or thyroid disease, psychiatric medicines, pregnancy or breastfeeding, and kidney or liver disease. A short pair list cannot evaluate all personal risks.
Important Disclaimer
This tool and guides are for educational purposes only. They do not constitute medical advice, diagnosis, or treatment. Notes identify their evidence level and link to original sources where an assessment is provided. Missing or limited data in this tool is not evidence of no interaction.
Peptide products include approved medicines, compounded preparations and investigational substances with different evidence and product instructions. Regulatory status alone does not establish a scientific benefit or a combined-use assessment. Consult a pharmacist or prescriber before changing treatment.
Updated September 8, 2026: revised evidence categories and source links, corrected generic insulin and medication-spacing instructions, and distinguished unassessed pairs from documented interactions. This is an editorial review, not an individual clinical assessment.